Market Research Reports Global Sex Hormones Market Report 2019.docx | Page 2
Drospirenone
On the basis of End Use Industry, the market is split into:
Topical
Inhalation
Injection
Oral
The report is a compilation of first-hand information, qualitative and quantitative assessment by
industry analysts, inputs from industry experts and industry participants across the value chain. The
report provides in-depth analysis of parent market trends, macro-economic indicators and governing
factors along with market attractiveness as per segments. The report also maps the qualitative
impact of various market factors on market segments and geographies.
Some of the major players that operate in the Global Sex Hormones Market are Pfizer, Novartis,
Merck, Sanofi, Bayer, GSK, AstraZeneca, Cipla, Zizhu Pharma.
Latest Industry Updates:
Pfizer – Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.
(NYSE: PFE) today announced updated results from the Phase 1/2 Alta study evaluating
investigational SB-525 gene therapy for severe hemophilia A. The data showed that SB-525 was
generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity
levels. The first two patients treated at the 3e13 vg/kg dose rapidly achieved normal levels of FVIII
activity as measured using a chromogenic assay, with no reported bleeding events, and the response
continues to be durable for as long as 24 weeks, the extent of follow-up.
The two patients more recently treated at the 3e13 vg/kg dose level are demonstrating FVIII activity
kinetics that appear consistent with the first two patients treated in this dose cohort at similar early
time points. Data from 10 patients treated with SB-525 were presented during an oral presentation
on July 6 at the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH), in
Melbourne, Australia. The SB-525 ISTH presentation slides, which include the full data set, are
available on Sangamo’s website in the Investors and Media section under Events and Presentations.
“The initial results with SB-525 gene therapy for patients with severe hemophilia A continue to look
very promising,” said Barbara Konkle, M.D., Bloodworks Northwest, Professor of Medicine at
University of Washington and a Principal Investigator of the Alta study. “It is encouraging that
patients in the 3e13 vg/kg cohort have attained normal Factor VIII levels within 5-7 weeks of
treatment with SB-525 gene therapy and have sustained Factor VIII activity with no bleeding
episodes. It will be important to continue to follow these patients to understand the potential long-
term durability of this gene therapy.”
Market segment by Regions/Countries, this report covers:
1 North America Country (United States, Canada)
2 South America
3 Asia Country (China, Japan, India, Korea)